Enterprise Value

329.7M

Cash

21.63M

Avg Qtr Burn

-9.215M

Short % of Float

0.06%

Insider Ownership

0.00%

Institutional Own.

9.93%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NBTXR3 + Cetuximab Details
Head and neck cancer, Cancer

Phase 3

Interim Update

NBTXR3 + Immunotherapy Details
Head and neck cancer, Cancer

Phase 3

Update

NBTXR3 Details
Cancer, Non-small cell lung carcinoma

Phase 2

Update

NBTXR3 + immunotherapy Details
Cancer, Esophageal cancer

Phase 1/2

Data readout

NBTXR3 Details
Cancer, Pancreatic cancer

Phase 1b

Data readout

NBTXR3 Details
Head and neck cancer, Cancer

Phase 1

Data readout

NBTXR3 + Anti-PD-1 Details
Head and neck cancer, Cancer

Phase 1

Update